drugset / Trial / NCT04120415
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)
Phase 2
Completed
2 enrolled
ANRS, Emerging Infectious Diseases
Centre Hospitalier Universitaire Vaudois · collabChelsea and Westminster Hospital, UK · collabErasmus Medical Center · collabEuroVacc Foundation · collabEuropean AIDS Treatment Group (EATG) · collabEuropean Commission · collabEuropean Georges Pompidou Hospital · collabHenri Mondor University Hospital · collabHospital Clinic of Barcelona · collabImperial College London · collabInstitut d'Investigacions Biomèdiques August Pi i Sunyer · collabIstituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS · collabMedical Research Council · collabSaint-Louis Hospital, Paris, France · collabSwiss Government · collabUniversity College London Hospitals · collabUniversity of Liverpool · collabUniversitätsklinikum Hamburg-Eppendorf · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.
Timeline
- Start
- 2022-06-21
- Primary completion
- 2023-07-12
- Completion
- 2023-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVA HIV-B | Vaccine | 0.5 ml | Intramuscular |
| Subject | Vedolizumab | Monoclonal antibody | 300 mg | Intravenous |